Clinical Trials Logo

Clinical Trial Summary

The objectives of this study are: - To evaluate the efficacy of Nyxol to expedite the reversal of pharmacologically-induced mydriasis across multiple mydriatic agents with an emphasis on phenylephrine - To evaluate the efficacy of Nyxol to return subjects to baseline accommodation after worsening (with cycloplegic agents tropicamide and Paremyd) - To evaluate the safety of Nyxol - To evaluate any additional benefits of the reversal of pharmacologically-induced mydriasis


Clinical Trial Description

A randomized, parallel arm, double-masked, placebo-controlled Phase 3 study in at least 168 randomized subjects (160 completed), evaluating the safety and efficacy of Nyxol in subjects with pharmacologically-induced mydriasis. Following the successful completion of screening, each subject will be stratified by eye color and then simultaneously be randomized to mydriatic agent (unmasked) and treatment (masked). Treatment randomization will be 1:1, Nyxol or placebo (vehicle). Stratification by iris color will be 1:1, light or dark irides. The mydriatic agent randomization will be 3:1:1 (2.5% phenylephrine, 1% tropicamide, and Paremyd). That is, approximately 60% of the randomized subjects will receive one drop of 2.5% phenylephrine 1 hour before treatment (96 completed subjects), approximately 20% will receive one drop of 1% tropicamide 1 hour before treatment (32 completed subjects), and approximately 20% will receive Paremyd 1 hour before treatment (32 completed subjects). At the treatment visit, subjects who have been randomized and stratified by iris color (1:1 [light/dark]) will receive one of three approved mydriatic agents approximately 1 hour prior to receiving study treatment. Measurements will be measured before (-1 hour /baseline) and 60 minutes after (maximum/0 minutes) the mydriatic agent instillation in each eye (i.e. right before the study treatment is administered), and at 30 minutes, 60 minutes, 90 minutes, 2 hours, 3 hours, 4 hours, and 6 hours after treatment dosing. Measurements will include pupil diameter (PD), distance and near visual acuity (VA), accommodation, and redness in each eye. At the Follow-Up Visit, which is 1 day after Visit 1, measurements will again be recorded 24 hours after treatment dosing. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04620213
Study type Interventional
Source Ocuphire Pharma, Inc.
Contact
Status Completed
Phase Phase 3
Start date November 18, 2020
Completion date March 15, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03638726 - Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification Phase 4
Completed NCT02946125 - Study of the Safety, Efficacy and PK of EYN-1601 in Dilation of the Pupil Phase 2
Completed NCT06217796 - Safety and Efficacy of Fixed Combination Phenylephrine-Tropicamide for Pupil Dilation Phase 4
Completed NCT05134974 - Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3) Phase 3
Completed NCT03751631 - Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation Phase 3
Completed NCT04907474 - Evaluation of Pupil Dilation Speed With the MAP Dispenser Phase 4
Completed NCT05880433 - The Effects of Mydriatic Eye Drops in Retinopathy of Prematurity Examinations
Terminated NCT00690222 - Intracameral Mydriasis Versus Topical Mydriasis in Cataract Surgery N/A
Recruiting NCT05829122 - Sutureless Intrascleral Intraocular Lens Fixation and Modified Iris Cerclage Pupilloplasty N/A
Completed NCT04396301 - Effect of Intracameral Injection of Mydriatic Plus Anaesthetic Combination on Corneal Endothelial Count in Phaco Phase 3
Completed NCT05223478 - Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects Phase 3
Completed NCT03751098 - Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation Phase 3
Completed NCT04024891 - Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis Phase 2